Praxis Precision Medicines Gears Up for December Investor Conferences
BOSTON -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, is excited to announce its participation in two notable investor conferences this December.
Participation at Major Events
Managing directors at Praxis will engage in a fireside chat at the prestigious Piper Sandler 36th Annual Healthcare Conference held in New York. This discussion is scheduled for December 4, 2024, at 2:00 PM ET. Attendees will have the opportunity to gain insights into the company's strategy and therapeutic innovations.
Fireside Chat Details
During the fireside chat, attendees will learn about how Praxis is leveraging genetic insights to drive forward solutions for CNS conditions characterized by neuronal excitation-inhibition imbalances. This is essential for understanding the disruptive potential of their therapeutic candidates within the industry.
Panel Discussion at Oppenheimer Summit
Following this, Praxis will also take part in a panel called “Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts” at the Oppenheimer Movers in Rare Disease Summit on December 12, 2024, again in New York at the Westin Grand Central Hotel, also at 2:00 PM ET. This provides another platform for the company to highlight its exciting potential and imminent milestone catalysts.
Networking Opportunities
In addition to these key presentations, Praxis invites interested investors to schedule one-on-one meetings with company representatives throughout the conferences. Investors interested in meeting should reach out to their Piper Sandler or Oppenheimer contacts.
Availability of Webcasts
For those unable to attend in person, the Piper Sandler conference will feature a live webcast available on the Praxis website. A recording will be made accessible following the event, ensuring that all interested parties can stay informed about the company's progress and updates.
About Praxis Precision Medicines
Praxis Precision Medicines is dedicated to translating genetic insights into revolutionary treatments for CNS disorders, emphasizing the importance of maintaining neuronal balance. The company is utilizing innovative platforms like Cerebrum™, a proprietary small molecule platform, and Solidus™, an antisense oligonucleotide platform, to spearhead the discovery and development of therapies targeting rare and more common neurological diseases.
With a robust pipeline that includes multiple programs across various neurological disorder segments, Praxis is well-positioned to make significant advancements in this vital area of medicine. As they prepare for these crucial gatherings, the company remains committed to fostering a deeper understanding of their work among potential investors and stakeholders.
Frequently Asked Questions
What will Praxis discuss at the investor conferences?
Praxis will emphasize its strategic direction and innovative therapeutic candidates aimed at CNS disorders during these events.
How can investors contact Praxis for one-on-one meetings?
Investors are encouraged to reach out to their Piper Sandler or Oppenheimer contacts to arrange meetings with Praxis representatives.
When is the Piper Sandler fireside chat scheduled?
The Piper Sandler fireside chat is set for December 4, 2024, at 2:00 PM ET.
What is the Oppenheimer Movers in Rare Disease Summit?
This summit features various companies discussing their innovations and potential stock-moving catalysts within rare diseases.
Where can I find the recorded webcast of the presentations?
The recorded webcast will be available on the Praxis website following the events under the “Upcoming & Recent Events” section.
